+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Breast Cancer Screening Tests Market - Growth, Trends, and Forecast (2020 - 2025)

  • PDF Icon


  • 85 Pages
  • August 2020
  • Region: Europe
  • Mordor Intelligence
  • ID: 5176128
The Europe breast cancer screening test market is expected to register a CAGR of 4.1 % over the forecast period. Factors that are responsible for the growth of this market include the increasing awareness about the early detection of breast cancer, the growing incidence of breast cancer, and the increasing government initiatives and support. Early detection of breast cancer can lead to desired outcomes, including increased survival rate, number of treatment options, and improved quality of life. And the rising incidence of breast cancer is helping the market to grow in the forecast period. According to EUROPA DONNA, The European Breast Cancer Coalition, breast cancer is the most common cancer in the Europe region women with an incidence of 562,500 in 2018, and 1 in 8 women in the EU-28 will develop breast cancer before the age of 85. Breast cancer, therefore, affects many women during their years dedicated to working and raising a family which is likely to drive the market growth during the forecast period.

Key Market Trends

Imaging Test is Expected to Dominate in the Europe Breast Cancer Screening Test Market

The most commonly used screening test for breast cancer is the imaging test and these imaging tests are considered as the most reliable ones. Mammograms are the most widely used tests to screen breast cancer. Since mammography is the gold standard technique used to screen breast cancer, governments and other healthcare organizations around the world are taking initiatives to provide women, between the ages of 50 and 75, access to mammography screening. This is increasing the global demand for mammography while laboratory and blood tests and other imaging tests are gaining popularity.

Digital breast tomosynthesis can increase the diagnostic accuracy of mammography and is used for the assessment of equivocal or suspicious mammography findings. In April 2019, Kheiron Medical Technologies launched Mia™, a breast cancer screening software product in Europe, the United Kingdom, and the United States. Other modalities, such as ultrasound and contrast-enhanced magnetic resonance imaging (MRI) play an important role in the diagnostics, staging, and follow-up of breast cancer.

Competitive Landscape

The Europe breast cancer screening test market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. With the increasing awareness among the population and rising advances in the screening test, a few other smaller players are expected to enter the market and may come to hold a substantial share. Some of the major players of the market are Allengers, Myriad Genetics, Hologic Inc., and Siemens Healthineers, among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidence of Breast Cancer
4.2.2 Increasing Government Initiatives and Support on Awareness about Early Detection of Breast Cancer
4.3 Market Restraints
4.3.1 High Cost of Breast Cancer Screening Tests
4.3.2 Side Effects of Radiation during Screening Tests and Errors in Screening
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Test Type
5.1.1 Genomic Tests
5.1.2 Imaging Test Mammograms Ultrasound MRI Tomography Other Imaging Tests
5.2 Geography
5.2.1 Europe Germany France United Kingdom Italy Spain Rest of Europe
6.1 Company Profiles
6.1.1 Allengers
6.1.2 Agendia BV
6.1.3 Myriad Genetics, Inc.
6.1.4 Koninklijke Philips N.V.
6.1.5 GE Healthcare
6.1.6 Fujifilm Holdings Corporation
6.1.7 NanoString Technologies, Inc.
6.1.8 Siemens Healthineers
6.1.9 Hologic Inc.
6.1.10 Quest Diagnostics Incorporated

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Allengers
  • Agendia BV
  • Myriad Genetics, Inc.
  • Koninklijke Philips N.V.
  • GE Healthcare
  • Fujifilm Holdings Corporation
  • NanoString Technologies, Inc.
  • Siemens Healthineers
  • Hologic Inc.
  • Quest Diagnostics Incorporated